EDAP TMS S.A. (NASDAQ:EDAP) is reporting third quarter financial results on Wednesday 18th November 2020, after market close.
According to analysts surveyed by Thomson Reuters, EDAP is expected to report 3Q20 loss of $ 0.02 per share from revenue of $ 9.29 million.
For the full year, analysts anticipate top line of $ 42.01 million, while looking forward to loss of $ 0.05 per share bottom line.
Previous Quarter Performance
EDAP TMS S.A. revealed loss for the second quarter of $ 0.01 per share, from the revenue of $ 10.24 million. The quarterly revenues down 25.53 percent compared with the same quarter last year. Wall street analysts are predicting, EDAP to report 2Q20 loss of $ 0.08 per share from revenue of $ 6.72 million. The bottom line results beat street analysts by $ 0.07 or 87.50 percent, at the same time, top line results outshined analysts by $ 3.52 million or 52.38 percent.
Stock Performance
Shares of EDAP TMS S.A. traded up $ 0.00 or 0.00 percent on Tuesday, reaching $ 4.40 with volume of 112.00 thousand shares. EDAP TMS S.A. has traded high as $ 4.54 and has cracked $ 4.35 on the downward trend
According to the previous trading day, closing price of $ 4.40, representing a 201.37 % increase from the 52 week low of $ 1.46 and a 18.37 % decrease over the 52 week high of $ 5.39.
The company has a market capital of $ 128.22 million and is part of the Healthcare sector and Medical Devices industry.
EDAP TMS S.A., together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally-invasive medical devices for the treatment of urological diseases worldwide. It operates in two divisions, High Intensity Focused Ultrasound (HIFU) and Urological Devices and Services (UDS). The HIFU division develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications.
